Switch theme
Sign up to access all valuation multiples
Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses, and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective, and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue principally from the provision of AI-based software solutions, sales of hardware devices, and other services. Geographically, the company generates the majority of its revenue from Mainland China.
2015
282
LTM Revenue $26.1M
LTM EBITDA -$30.2M
$53.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Airdoc has a last 12-month revenue (LTM) of $26.1M and a last 12-month EBITDA of -$30.2M.
In the most recent fiscal year, Airdoc achieved revenue of $20.0M and an EBITDA of -$30.8M.
Airdoc expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Airdoc valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $26.1M | XXX | $20.0M | XXX | XXX | XXX |
| Gross Profit | $13.3M | XXX | $11.1M | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | -$30.2M | XXX | -$30.8M | XXX | XXX | XXX |
| EBITDA Margin | -116% | XXX | -155% | XXX | XXX | XXX |
| EBIT | -$30.6M | XXX | -$25.4M | XXX | XXX | XXX |
| EBIT Margin | -118% | XXX | -127% | XXX | XXX | XXX |
| Net Profit | -$29.7M | XXX | -$32.6M | XXX | XXX | XXX |
| Net Margin | -114% | XXX | -163% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Airdoc's stock price is HKD 12 (or $2).
Airdoc has current market cap of HKD 1.2B (or $157M), and EV of HKD 420M (or $53.6M).
See Airdoc trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $53.6M | $157M | XXX | XXX | XXX | XXX | $-0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Airdoc has market cap of $157M and EV of $53.6M.
Airdoc's trades at 2.7x EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Airdoc's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Airdoc has a P/E ratio of -5.7x.
See valuation multiples for Airdoc and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $157M | XXX | $157M | XXX | XXX | XXX |
| EV (current) | $53.6M | XXX | $53.6M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | -1.9x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -1.9x | XXX | -2.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.7x | XXX | -4.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAirdoc's last 12 month revenue growth is 28%
Airdoc's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Airdoc's rule of 40 is -28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Airdoc's rule of X is -46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Airdoc and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Margin | -116% | XXX | -155% | XXX | XXX | XXX |
| EBITDA Growth | -62% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -28% | XXX | -127% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -46% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 65% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 182% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Airdoc acquired XXX companies to date.
Last acquisition by Airdoc was XXXXXXXX, XXXXX XXXXX XXXXXX . Airdoc acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Airdoc founded? | Airdoc was founded in 2015. |
| Where is Airdoc headquartered? | Airdoc is headquartered in Hong Kong. |
| How many employees does Airdoc have? | As of today, Airdoc has 282 employees. |
| Is Airdoc publicy listed? | Yes, Airdoc is a public company listed on HKG. |
| What is the stock symbol of Airdoc? | Airdoc trades under 02251 ticker. |
| When did Airdoc go public? | Airdoc went public in 2021. |
| Who are competitors of Airdoc? | Similar companies to Airdoc include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Airdoc? | Airdoc's current market cap is $157M |
| What is the current revenue of Airdoc? | Airdoc's last 12 months revenue is $26.1M. |
| What is the current revenue growth of Airdoc? | Airdoc revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of Airdoc? | Current revenue multiple of Airdoc is 2.2x. |
| Is Airdoc profitable? | Yes, Airdoc is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Airdoc? | Airdoc's last 12 months EBITDA is -$30.2M. |
| What is Airdoc's EBITDA margin? | Airdoc's last 12 months EBITDA margin is -116%. |
| What is the current EV/EBITDA multiple of Airdoc? | Current EBITDA multiple of Airdoc is -1.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
